Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Biomaterials. 2022 Dec 24;293:121960. doi: 10.1016/j.biomaterials.2022.121960

Figure 5. ND vs. Diseased wECM Lung ECM Composition.

Figure 5.

Proteomic analysis of wECM samples obtained from ND (n=6), COPD (n=3), and IPF (n=3) decellularized patient lung lobes. (A) Schematic depicting samples utilized for proteomic analysis. (B) PCA plot demonstrating similarity of wECM protein composition across lung conditions. Each data point represents the relative abundance (%) of all individual wECM proteins (normalized to abundance of total wECM composition) within each respective sample.(C) Relative abundance (%) of wECM protein type (normalized to total wECM composition within each respective sample) within each respective sample). (D) Comparison of normalized individual wECM proteins across lung conditions. Bars in (C,D) indicate mean +/− SEM; *p<0.05, **p<0.01 using Dunn’s method. Statistical trends are identified if 0.05≤p<0.1. (E) Qualitative Venn diagram depicting differences in wECM proteins of pooled samples by condition.